Robert M. Cox

Robert M. Cox

Auto-generated profile, based on publicly available information

Robert M. Cox

Center for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia 30303, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2020 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
RCRobert M. Cox
Robert M. Cox
JWJosef D. Wolf
Josef D. Wolf
Richard PlemperRichard Plemper
Richard Plemper

5 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRobert M. Cox
Robert M. Cox
JWJosef D. Wolf
Josef D. Wolf
CLCarolin M. Lieber
Carolin M. Lieber
JSJulien Sourimant
Julien Sourimant
MLMichelle J. Lin
Michelle J. Lin
Richard PlemperRichard Plemper
Richard Plemper
Remdesivir is an antiviral approved for COVID-19 treatment, but its wider use is limited by intravenous delivery. An orally bioavailable remdesivir analog may boost therapeutic benefit by facilitating early administration to non-hospitalized patients. This study characterizes the anti-SARS-CoV-2 efficacy of GS-621763, an oral prodrug of remdesivir parent nucleoside GS-441524. Both GS-621763 and GS-441524 inhibit SARS-CoV-2, including variants of concern (VOC) in cell culture and human airway epithelium organoids. Oral GS-621763 is efficiently converted to plasma metabolite GS-441524, and in lungs to the triphosphate metabolite identical to that generated by remdesivir, demonstrating a consistent mechanism of activity. Twice-daily oral administration of 10 mg/kg GS-621763 reduces SARS-CoV-2 burden to near-undetectable levels in ferrets. When dosed therapeutically against VOC P.1 gamma γ, oral GS-621763 blocks virus replication and prevents transmission to untreated contact animals. These results demonstrate therapeutic efficacy of a much-needed orally bioavailable analog of remdesivir in a relevant animal model of SARS-CoV-2 infection.

13 July 2020 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
RCRobert M. Cox
Robert M. Cox
JSJulien Sourimant
Julien Sourimant
MTMart Toots
Mart Toots
JYJeong-Joong Yoon
Jeong-Joong Yoon
SISatoshi Ikegame
Satoshi Ikegame
Richard PlemperRichard Plemper
Richard Plemper

29 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLCarolin M. Lieber
Carolin M. Lieber
RCRobert M. Cox
Robert M. Cox
JSJulien Sourimant
Julien Sourimant
JWJosef D. Wolf
Josef D. Wolf
KJKate Juergens
Kate Juergens
Richard PlemperRichard Plemper
Richard Plemper
SARS-CoV-2 variants of concern (VOC) have triggered infection waves. Oral antivirals such as molnupiravir promise to improve disease management, but efficacy against VOC delta was questioned and potency against omicron is unknown. This study evaluates molnupiravir against VOC in human airway epithelium organoids, ferrets, and a lethal Roborovski dwarf hamster model of severe COVID-19-like lung injury. VOC were equally inhibited by molnupiravir in cells and organoids. Treatment reduced shedding in ferrets and prevented transmission. Pathogenicity in dwarf hamsters was VOC-dependent and highest for delta, gamma, and omicron. All molnupiravir-treated dwarf hamsters survived, showing reduction in lung virus load from one (delta) to four (gamma) orders of magnitude. Treatment effect size varied in individual dwarf hamsters infected with omicron and was significant in males, but not females. The dwarf hamster model recapitulates mixed efficacy of molnupiravir in human trials and alerts that benefit must be reassessed in vivo as VOC evolve.

7 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRobert M. Cox
Robert M. Cox
CLCarolin M. Lieber
Carolin M. Lieber
JWJosef D. Wolf
Josef D. Wolf
AKAmirhossein Karimi
Amirhossein Karimi
NLNicole A. P. Lieberman
Nicole A. P. Lieberman
Richard PlemperRichard Plemper
Richard Plemper
Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials suggested greater efficacy of paxlovid, but recent studies indicated comparable potency in older adults. Here, we compare both drugs in two animal models; the Roborovski dwarf hamster model for severe COVID-19-like lung infection and the ferret SARS-CoV-2 transmission model. Dwarf hamsters treated with either drug survive VOC omicron infection with equivalent lung titer reduction. Viral RNA copies in the upper respiratory tract of female ferrets receiving 1.25 mg/kg molnupiravir twice-daily are not significantly reduced, but infectious titers are lowered by >2 log orders and direct-contact transmission is stopped. Female ferrets dosed with 20 or 100 mg/kg nirmatrelvir/ritonavir twice-daily show 1–2 log order reduction of viral RNA copies and infectious titers, which correlates with low nirmatrelvir exposure in nasal turbinates. Virus replication resurges towards nirmatrelvir/ritonavir treatment end and virus transmits efficiently (20 mg/kg group) or partially (100 mg/kg group). Prophylactic treatment with 20 mg/kg nirmatrelvir/ritonavir does not prevent spread from infected ferrets, but prophylactic 5 mg/kg molnupiravir or 100 mg/kg nirmatrelvir/ritonavir block productive transmission. These data confirm reports of similar efficacy in older adults and inform on possible epidemiologic benefit of antiviral treatment.

1 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MRMichael H. J. Rhodin
Michael H. J. Rhodin
ARArchie C. Reyes
Archie C. Reyes
ABAnand Balakrishnan
Anand Balakrishnan
NBNalini Bisht
Nalini Bisht
NKNicole M. Kelly
Nicole M. Kelly
YOYat Sun Or
Yat Sun Or
The COVID-19 pandemic has led to the deaths of millions of people and severe global economic impacts. Small molecule therapeutics have played an important role in the fight against SARS-CoV-2, the virus responsible for COVID-19, but their efficacy has been limited in scope and availability, with many people unable to access their benefits, and better options are needed. EDP-235 is specifically designed to inhibit the SARS-CoV-2 3CLpro, with potent nanomolar activity against all SARS-CoV-2 variants to date, as well as clinically relevant human and zoonotic coronaviruses. EDP-235 maintains potency against variants bearing mutations associated with nirmatrelvir resistance. Additionally, EDP-235 demonstrates a ≥ 500-fold selectivity index against multiple host proteases. In a male Syrian hamster model of COVID-19, EDP-235 suppresses SARS-CoV-2 replication and viral-induced hamster lung pathology. In a female ferret model, EDP-235 inhibits production of SARS-CoV-2 infectious virus and RNA at multiple anatomical sites. Furthermore, SARS-CoV-2 contact transmission does not occur when naïve ferrets are co-housed with infected, EDP-235-treated ferrets. Collectively, these results demonstrate that EDP-235 is a broad-spectrum coronavirus inhibitor with efficacy in animal models of primary infection and transmission.